NCT04634747 2022-04-20Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast CancerOncoPep, Inc.Phase 2 Unknown53 enrolled